<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397475</url>
  </required_header>
  <id_info>
    <org_study_id>142/06</org_study_id>
    <nct_id>NCT00397475</nct_id>
  </id_info>
  <brief_title>Evaluation of Colecalciferol Substitution in Dialysis Patients</brief_title>
  <official_title>Evaluation of Colecalciferol Substitution in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of a colecalciferol substitution in&#xD;
      dialysis patients on bone metabolism and immune system&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD14/CD16-Monocyte-Subsets (Frequency)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Production of Cytokines: IFN-γ, TNF-α</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of Calcium, Phosphorus, iPTH, hsCRP, alkaline phosphatase</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Th1/Th2- and Tc1/Tc2-Lymphocyte-Frequency</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>RENAL INSUFFICIENCY, CHRONIC</condition>
  <condition>Hyperparathyroidism, Secondary</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colecalciferol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Serum 25-OH-Vit.D-levels &lt; 60 ng/ml&#xD;
&#xD;
          2. Age &gt; 18 years&#xD;
&#xD;
          3. dialysis treatment &gt; 3 Months&#xD;
&#xD;
          4. signed written informed consent&#xD;
&#xD;
          5. Serum-Calcium-levels &lt; 2,6 mmol/l within the last 4 weeks&#xD;
&#xD;
          6. Serum-Phosphate-levels &lt; 7,0 mg/dl within the last 4 weeks&#xD;
&#xD;
          7. Ca x P-Product &lt; 75 mg2/dl2 within the last 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serum 25-OH-Vit.-D-levels &gt; 60 ng/ml&#xD;
&#xD;
          2. concommitant participation in another interventional trial&#xD;
&#xD;
          3. psychiatric disorders preventing from valid informed consent&#xD;
&#xD;
          4. Hyperphosphatemia (&gt; 7,0 mg/dl) within the last 4 weeks&#xD;
&#xD;
          5. Hypercalcemia (&gt; 2,6 mmol/l) within the last 4 weeks&#xD;
&#xD;
          6. Ca x P-Product &gt; 75 mg2/dl2 within the last 4 weeks&#xD;
&#xD;
          7. pregnancy or lactation&#xD;
&#xD;
          8. known malignancy&#xD;
&#xD;
          9. liver disease, defined as 2-fold upper limit of ASAT-, or ALAT-levels&#xD;
&#xD;
         10. PTH levels &lt; 50 pg/ml&#xD;
&#xD;
         11. current clinically relevant infections treated with antibiotic therapy and raised&#xD;
             hsCRP levels&#xD;
&#xD;
         12. Chronic viral Infectious diseases (e.g. HIV, Hepatitis B or C)&#xD;
&#xD;
         13. Immunosuppressant Medication&#xD;
&#xD;
         14. known hematologic disorders, other than renal anemia&#xD;
&#xD;
         15. age below 18 years&#xD;
&#xD;
         16. known anaphylactic reaction against the study medication or other ingredients of the&#xD;
             study drug preparation&#xD;
&#xD;
         17. renal calculus&#xD;
&#xD;
         18. Pseudohypoparathyroidism&#xD;
&#xD;
         19. Medication including cardiac glycosides&#xD;
&#xD;
         20. Sarkoidosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Seibert, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Saarland, Dpt. of Internal Medicine IV, Div. of Nephrology and Hypertension</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Saarland, Dpt. of Internal Medicine IV, Div. of Nephrology and Hypertension</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>November 7, 2006</study_first_submitted>
  <study_first_submitted_qc>November 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2006</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

